Abstract View: 9333
PDF Download: 4213
Full Text View: 9
Original
Oral repaglinide versus insulin injection in type II diabetes mellitus; a randomized clinical trial
Hosein Chiti
1,2, Maryam Hajipour Manjili
2, Aiyoub Pezeshgi
2, Seyednouraddin Mousavinasab
3, Zahra Abbaspour
2, Masoud Asadi-Khiavi
4,5*1 Zanjan Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
2 Department of Internal Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
3 Department of Biostatistics, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
4 Zanjan Applied Pharmacology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran 5Department of Pharmacotherapy, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan
5 Department of Pharmacotherapy, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran
*Corresponding Author: *Corresponding author: Masoud Asadi-Khiavi, , Email:
makhiavi@gmail.com
Abstract
Introduction: Glycemic control at the level of normal condition is considered as a key point for preventing of complications like metabolic disturbances as well as renal pathologies in type II diabetes mellitus (DM).
Objectives: Presented study was designed to find suitable method for reducing hyperglycemic pathologies like normalizing of albuminuria, postprandial blood sugar (BS), HbA1c, fasting blood sugar (FBS) and C-peptide levels by administration of insulin injection versus oral repaglinide.
Patients and Methods: A total of 56 cases of type II DM were enrolled in this study and randomly divided into two groups of 28 subjects receiving regular insulin (control group) and repaglinide tablets (cases group) in accordance with inclusion and exclusion criteria. Glycemic profile and levels of albuminuria were measured and analyzed during 12 weeks.
Results: Changes in levels of FBS, 2 hours postprandial (2hpp) BS and HbA1c were not showed in both groups (P = 0.096) but C-peptide levels were decreased in the repaglinide group (P = 0.001). Hypoglycemia was observed in 21.4% of control group. Statistically significant reduction in HbA1c levels was not observed despite a greater impact of regular soluble insulin on postprandial glucose (P = 0.096). Weight gain in insulin group was more (P = 0.042) and hypoglycemic events were lower in repaglinide group. Additionally, reduction in microalbuminuria was not statistically significant (P = 0.73) in both groups.
Conclusion: Based on our findings, repaglinide is suitable candidate for preventing undesirable side effects through regular soluble insulin using for type II DM treatment.
Implication for health policy/practice/research/medical education:
In a study on 56 patients with type II DM who divided into case and control groups, and received repaglinide tablets for 28 patients (case group) and injection of regular insulin for other 28 patients (control group), we found repaglinide decreased proportion of microalbuminuria and severity and frequency of hypoglycemia but in the manner of non-statistical significance differences.
Please cite this paper as: Chiti H, Hajipour Manjili M, Pezeshgi A, Mousavinasab S, Abbaspour Z, Asadi-Khiavi M. Oral repaglinide versus insulin injection in type II diabetes mellitus; a randomized clinical trial. J Nephropharmacol. 2018;7(1):1-4. DOI: 10.15171/npj.2018.01.